PharMerica Board Unanimously Rejects Unsolicited Conditional Tender Offer from Omnicare

PharMerica Corporation (NYSE: PMC), a national provider of institutional pharmacy and hospital pharmacy management services, today announced that its Board of Directors, after careful consideration with its independent financial and outside legal advisors, voted unanimously to reject the unsolicited tender offer made by Omnicare (NYSE: OCR) to acquire PharMerica for $15.00 per share in cash. The Board determined that the offer undervalues PharMerica and is not in the best interests of PharMerica's stockholders. In addition to undervaluing PharMerica and its future prospects, the Board believes the offer is illusory because it is subject to significant regulatory and other uncertainty. The Board unanimously recommends that PharMerica stockholders reject Omnicare's offer and not tender their shares to Omnicare.

The Board noted that the value offered by Omnicare is unchanged from the unsolicited proposal it first made privately on July 19, 2011 and subsequently made public on August 23, 2011.

"The PharMerica Board of Directors is unanimous in its well-informed belief that Omnicare's offer is lacking in both price and certainty of closing," said Gregory S. Weishar, PharMerica Chief Executive Officer. "The PharMerica Board believes that the continued pursuit of our strategic plan will yield greater value for PharMerica stockholders than the Omnicare offer. Omnicare also remains stubbornly unwilling to provide any assurance to PharMerica stockholders that it will be in a position to complete a transaction in a timely manner at any price -- and despite its professed confidence in attaining regulatory approval refuses to take on the contractual risk of closing. The PharMerica Board strongly urges stockholders to reject Omnicare's deficient offer and not to tender their shares to Omnicare."

The Board's reasons for rejecting Omnicare's unsolicited offer include its beliefs that:

  • Omnicare's unsolicited offer undervalues PharMerica and its future prospects. ◦The Board has confidence in PharMerica's strategic plan, which is focused on client retention, customer service, and improving its core pharmacy services and acquisitions, and believes that execution of the plan will deliver greater value to its stockholders than would be obtained under the current Omnicare offer.

◦PharMerica recently completed acquisitions of Ark Pharmacy and ChemRx, and is just beginning to realize the significant value creation potential of these acquisitions.
◦Omnicare's offer fails to appropriately compensate PharMerica stockholders for the synergies Omnicare would derive from combining the largest and second largest players in the institutional pharmacy market.
◦PharMerica is the second largest institutional pharmacy services company in the United States based on revenues and is the largest remaining independent public company in the institutional pharmacy market. Omnicare's offer does not reflect the unique strategic value of PharMerica to Omnicare.

 

 

  • The offer is illusory because it is subject to significant regulatory and other uncertainty. ◦A transaction with Omnicare would likely undergo a lengthy regulatory review process with no assurance of Omnicare's ability to complete a transaction on a timely basis or at all. Antitrust clearance to combine competitors with #1 and #2 market share in institutional pharmacy is likely to be difficult to achieve and involve lengthy administrative and court proceedings.

◦Even if the antitrust issues could eventually be resolved in a satisfactory manner, the offer introduces unacceptably high risk to PharMerica stockholders and would have a material adverse effect on PharMerica's ability to attract and retain key personnel, employees and customers.
◦In light of recent actions by the Department of Justice, including its decision to sue to stop AT&T's proposed acquisition of T-Mobile USA, the PharMerica Board believes the current environment is not conducive to obtaining timely regulatory approval for a combination with Omnicare.
◦While Omnicare has publicly expressed its confidence in a timely regulatory approval, it has been unwilling to take on the contractual risk of closing.
 ◦Given the regulatory uncertainty and the significant conditionality of Omnicare's offer, there is considerable uncertainty regarding the offer and the timing of PharMerica stockholders receiving the $15.00 that Omnicare claims to be offering.
◦Because Omnicare is a competitor of PharMerica, there are also serious competitive risks to PharMerica and its business in providing non-public information to Omnicare if the transaction is not completed due to antitrust, regulatory, or other issues.

 

 

  • The timing of Omnicare's unsolicited offer is opportunistic and disadvantageous to PharMerica's stockholders. ◦The offer is being made at a time when Omnicare can take advantage of PharMerica's lower stock valuation resulting from regulatory uncertainty in the healthcare industry due to new healthcare legislation.

◦The offer is being made in advance of the wave of branded to generic drug conversions that will happen in 2012 and beyond, which is expected to be beneficial to PharMerica's operating results.
◦After its unsolicited proposal was rejected privately in July as being inadequate, Omnicare publicized it during a period of market volatility in order to claim an inflated premium.

 

The full basis for the Board's recommendation is set forth in PharMerica's Schedule 14D-9 filed today with the Securities and Exchange Commissions.

Deutsche Bank Securities Inc. is acting as financial advisor and Holland & Knight LLP is acting as legal advisor to PharMerica.

About PharMerica

PharMerica Corporation is a leading institutional pharmacy services company servicing healthcare facilities in the United States. PharMerica operates institutional pharmacies in 44 states. PharMerica's customers are institutional healthcare providers, such as nursing centers, assisted living facilities, hospitals and other long-term care providers. The Company also provides pharmacy management services to long-term care hospitals.

Additional Information

This communication does not constitute an offer to buy or solicitation of an offer to sell any securities. In response to the tender offer, PharMerica will file a solicitation/recommendation statement on Schedule 14D-9 with the U.S. Securities and Exchange Commission ("SEC"). INVESTORS AND STOCKHOLDERS OF PHARMERICA ARE URGED TO READ THESE AND OTHER DOCUMENTS FILED WITH THE SEC CAREFULLY IN THEIR ENTIRETY BECAUSE THEY WILL CONTAIN IMPORTANT INFORMATION. Investors and stockholders may obtain free copies of these documents and other documents filed with the SEC by PharMerica through the web site maintained by the SEC at http://www.sec.gov. In addition, documents filed with the SEC by PharMerica may be obtained free of charge by contacting PharMerica's information agent, Georgeson Inc., at (866) 647-8872.

Suggested Articles

Look out, diabetes market: Novo Nordisk won its FDA nod for highly anticipated Rybelsus to control blood sugar in patients with Type 2 diabetes.

Insys is in fire sale mode as part of its bankruptcy plan, and now it’s been given the go-ahead to sell the opioid that helped get it there.

GSK CEO Emma Walmsley could soon have a new title: Microsoft board member. The software giant has nominated her to its board of directors.